Slingshot members are tracking this event:

IMBRUVICA (ibrutinib) Approved by U.S. FDA for the First-line Treatment of Chronic Lymphocytic Leukemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ABBV Community voting in process

Additional Information

Additional Relevant Details IMBRUVICA significantly prolonged progression-free survival (PFS; primary endpoint) as determined by an Independent Review Committee (IRC), reducing the risk of progression or death by 84% versus chlorambucil (hazard ratio [HR], 0.161 [95% confidence interval: 0.091, 0.283]; median PFS: not reached for IMBRUVICA vs. 18.9 months [95% confidence interval: 14.1, 22.0] for chlorambucil).1 IMBRUVICA was also associated with a significantly higher IRC-assessed overall response rate (ORR: a composite of complete and partial responses; 82.4% vs. 35.3%; P<0.0001) versus chlorambucil.1  Five patients (3.7 percent) in the IMBRUVICA arm achieved a complete response, compared to two patients (1.5 percent) in the chlorambucil arm.1
The safety of IMBRUVICA in this patient population was consistent with previously reported studies. The adverse reactions (AR) reported in the U.S. Prescribing Information reflect exposure to IMBRUVICA with a median duration of 17.4 months versus a median exposure to chlorambucil of 7.1 months: nearly 2.5 times longer exposure for IMBRUVICA. Warnings and Precautions include hemorrhage, infections, cytopenias, atrial fibrillation, hypertension, second primary malignancies, embryo-fetal toxicity and tumor lysis syndrome. The most commonly occurring adverse reactions of all Grades in CLL patients treated with IMBRUVICA in the RESONATE-2 trial (>20%) were diarrhea, musculoskeletal pain, cough and rash.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Imbruvica, Ibrutinib, Fda, Chronic Lymphocytic Leukemia, Resonate-2, Chlorambucil, Chemotherapy, Hematologic Malignancies, Tumor Suppressor Gene P53, Chromosome 17